Oura exploring how its ring could detect brain hemorrhages after Bill Ackman suggests it could have helped his daughter

Oura Health is exploring whether its flagship wearable ring can detect brain hemorrhages following Bill Ackman's public suggestion that such functionality could have prevented a critical delay in his daughter's emergency care. Ackman, founder and CEO of Pershing Square Capital Management, disclosed that his 26-year-old daughter Lucy suffered a brain hemorrhage in February 2026. Although the hemorrhage occurred around 9 a.m., Lucy was not discovered unconscious and transported to surgery until approximately 3:15 a.m. the following morning—a gap exceeding 19 hours. Ackman noted that retrospective analysis of data from Lucy's Oura Ring confirmed the approximate timing of the hemorrhage, establishing the ring's capacity to capture physiological signals associated with the event, even if detection was not actively flagged at the time.

In a public statement on X (formerly Twitter), Ackman articulated the potential value proposition: "I only wish @ouraring had an alert for this kind of a medical event. Imagine it could call a family member if the wearer doesn't cancel the alert." He emphasized that earlier detection and notification could have compressed the 19-hour window between hemorrhage onset and surgical intervention, potentially improving clinical outcomes. Tom Hale, CEO of Oura, responded publicly on Friday, confirming the company is actively investigating the feasibility of hemorrhage detection. "I keep coming back to the question of whether Oura could have seen anything that might have helped and then alerted Lucy," Hale stated, adding that he has directed his team to examine whether the ring's sensor array and algorithms could identify such acute neurological events.

The investigation represents a strategic expansion opportunity for Oura beyond its current positioning as a wellness and sleep-tracking device. The Oura Ring is established as one of the market-leading consumer wearable health trackers, and demonstration of acute medical event detection capability would substantially differentiate the product in both consumer and clinical segments. Concurrent with Oura's investigation, Ackman has committed $400 million to establish a dedicated brain research laboratory, signaling broad institutional capital commitment to neurological innovation and early detection technologies. This dual-track development—technological enhancement by Oura and financial investment in foundational neuroscience research—may accelerate development timelines for hemorrhage detection algorithms and validation studies.